An in silico approach to peptide-based dual-receptor targeting for IL13RA2 and VEGFR-2 extracellular domain

Saisha Islam1, Liana R Cutter1, Mary A Biggs1

  • 1Department of Chemistry and Biochemistry, Fordham University, 441 East Fordham Road, Bronx, NY, 10458, USA.

PubMed
Abstract

Insights

Researchers designed novel peptides targeting VEGFR-2 and IL13Rα2, crucial in cancer. Some variants showed strong dual-receptor binding and potential for developing new cancer therapies.

Area of Science:

  • Biochemistry and Molecular Biology
  • Computational Chemistry
  • Drug Discovery

Background:

  • Vascular endothelial growth factor receptor-2 (VEGFR-2) and interleukin 13 receptor subunit-2 (IL13Rα2) are overexpressed in various cancers, driving tumor progression.
  • These receptors are significant drug targets due to their roles in tumor cell proliferation, metastasis, and poor patient prognosis.

Purpose of the Study:

  • To design novel peptides capable of simultaneously targeting both VEGFR-2 and IL13Rα2.
  • To evaluate the binding affinities and stabilities of designed peptide variants using computational methods.
  • To explore the potential of these peptides as selective tumor-targeting agents and for future anti-cancer drug conjugation.

Main Methods:

  • Peptide design based on a tumor homing peptide (pep1IL) with single-point variations.
  • Molecular docking and molecular dynamics (MD) simulations to assess binding affinities and complex stability.
  • AlphaFold 3, DESMOND, AntiCP, ADMETlab3.0, PEP-FOLD3, MolProbity, and MCPep web servers were utilized for structural and property predictions.

Main Results:

  • Specific peptide variants, such as ACGEMGWVSCGGGS, demonstrated strong binding to both VEGFR-2 and IL13Rα2.
  • ACGHMGWVRCGGGS and ACGEMGWVRCGGGT showed stable complex formation with VEGFR-2 and IL13Rα2, respectively.
  • Disulfide-bridged variants also exhibited stable binding, with MM-GBSA indicating the importance of Van der Waals and electrostatic interactions.

Conclusions:

  • The study successfully designed selective peptide variants with potential for dual targeting of VEGFR-2 and IL13Rα2.
  • These peptides show promise as competitive inhibitors of angiogenic signaling and as agents for tumor targeting.
  • The designed peptides warrant further investigation for conjugation with anti-cancer drugs for therapeutic applications.

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...